Bafna Pharma.

{
  "main_header": {
    "sid": 852453,
    "name": "Bafna Pharma.",
    "stock_name": "Bafna Pharma.",
    "full_name": "Bafna Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/bafna-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "121.55",
    "chg": -5.52,
    "chgp": "-4.34%",
    "dir": -1,
    "prev_price": "127.07",
    "mcapval": "295.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532989,
    "symbol": "BAFNAPH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE878I01022",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "4.27 k",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bafna-pharma-852453-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bafna Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-is-rated-sell-3792694",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BafnaPharmaceut_mojoScore_3792694.png",
        "date": "2026-01-15 10:10:39",
        "description": "Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Why is Bafna Pharmaceuticals Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bafna-pharmaceuticals-ltd-fallingrising-3790742",
        "imagepath": "",
        "date": "2026-01-14 00:50:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Performance</strong></p>\n<p>The stock has been under pressure over the past week, registering a steep decline of 16.11%, significantly underperforming the Sensex’s modest 1.69% loss during the same period. Year-to-date, the stock has fallen by 16.43%, again far exceeding the benchmark’s 1.87% decline. This downward momentum has been persistent, with the stock experiencing six consecutive days of losses, cumulatively shedding over 16% in returns. On 13-Jan, the stock opened with a gap down of 4.47%, signalling immediate bearish sentiment among investors. Intraday, it touched a low of ₹126.55, marking a 4.85% drop from the previous close.</p>\n<p><strong>Technical Indicators and Investor Participation</strong></p>\n<p>From a technical standpoint, Bafna Pharmaceut..."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-is-rated-sell-3780496",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/BafnaPharmaceut_mojoScore_3780496.png",
        "date": "2026-01-04 10:10:27",
        "description": "Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 January 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Hits Lower Circuit Amid Heavy Selling Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-lower-circuit-amid-heavy-selling-pressure-3774819",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_stocks_hitting_lower_circuit_3774819.png",
        "date": "2025-12-30 10:00:16",
        "description": "Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 30 Dec 2025, hitting its lower circuit limit and closing at ₹151.89. The stock recorded a maximum daily loss of 2.24%, underperforming both its sector and the broader Sensex, as panic selling and unfilled supply weighed heavily on investor sentiment."
      },
      {
        "title": "Bafna Pharmaceuticals Hits Lower Circuit Amid Heavy Selling Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-hits-lower-circuit-amid-heavy-selling-pressure-3772923",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_stocks_hitting_lower_circuit_3772923.png",
        "date": "2025-12-29 10:00:32",
        "description": "Bafna Pharmaceuticals Ltd witnessed intense selling pressure on 29 Dec 2025, hitting its lower circuit limit and registering a maximum daily loss of 5%. The stock’s performance contrasted sharply with its sector and benchmark indices, reflecting a period of panic selling and unfilled supply that has unsettled investors."
      },
      {
        "title": "Bafna Pharmaceuticals Hits Lower Circuit Amid Heavy Selling Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-hits-lower-circuit-amid-heavy-selling-pressure-3770561",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_stocks_hitting_lower_circuit_3770561.png",
        "date": "2025-12-26 11:00:14",
        "description": "Bafna Pharmaceuticals Ltd witnessed a sharp decline on 26 Dec 2025, hitting its lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical company’s shares closed at ₹164.55, marking a maximum daily loss of 4.41%, amid heightened volatility and unfilled supply on the trading floor."
      },
      {
        "title": "Bafna Pharmaceuticals Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-hits-upper-circuit-amid-strong-buying-momentum-3768086",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_stocks_hitting_upper_circuit_3768086.png",
        "date": "2025-12-24 10:00:32",
        "description": "Bafna Pharmaceuticals Ltd witnessed robust buying interest on 24 Dec 2025, hitting its upper circuit limit with a 5.0% gain to close at ₹173.26. The stock outperformed its sector and broader market indices, reflecting heightened investor enthusiasm and a surge in demand that led to a regulatory trading freeze."
      },
      {
        "title": "Bafna Pharmaceuticals Sees Shift in Market Assessment Amid Technical and Financial Developments",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-upgraded-to-hold-by-marketsmojo-on-technical-and-financial-improvements-3767861",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_mojoScore_3767861.png",
        "date": "2025-12-24 08:20:52",
        "description": "Bafna Pharmaceuticals has experienced a notable revision in its market evaluation, reflecting changes across technical indicators, financial trends, valuation metrics, and overall quality considerations. This shift highlights evolving investor perspectives on the pharmaceutical company’s performance and outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Bafna Pharmaceuticals Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-hits-upper-circuit-amid-strong-buying-momentum-3766889",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BafnaPharmaceut_stocks_hitting_upper_circuit_3766889.png",
        "date": "2025-12-23 10:00:25",
        "description": "Bafna Pharmaceuticals Ltd witnessed robust buying interest on 23 Dec 2025, hitting its upper circuit limit with a maximum daily gain of 4.99%. The stock outperformed its sector and broader market indices, reflecting heightened investor enthusiasm and a surge in demand that led to a regulatory trading freeze."
      }
    ],
    "total": 264,
    "sid": "852453",
    "stock_news_url": "https://www.marketsmojo.com/news/bafna-pharmaceuticals-852453"
  },
  "announcements": [
    {
      "details": "Bafna Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on November 13, 2019.",
      "source": "NSE",
      "caption": "Bafna Pharmaceuticals Limited - Outcome of Board Meeting",
      "datetime": "14-Nov-2019"
    },
    {
      "details": " <table><tr><td>The Exchange had sought clarification from Bafna Pharmaceuticals Limited for the quarter ended 30-Jun-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed. </td></tr></table>",
      "source": "NSE",
      "caption": "Reply to Clarification- Financial results",
      "datetime": "27-Aug-2019"
    },
    {
      "details": " <table><tr><td>BAFNAPHARM: Members of the Exchange are hereby informed that the trading in Equity Shares of Bafna Pharmaceuticals Limited shall be suspended w.e.f. August 26, 2019 (i.e. closing hours of trading on August 23, 2019) on account of Reduction of Share Capital. </td></tr></table>",
      "source": "NSE",
      "caption": "Suspension of trading in equity shares",
      "datetime": "21-Aug-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13",
          "dt": "2013-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bafna Pharmaceuticals Ltd is Rated Sell

2026-01-15 10:10:39

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Why is Bafna Pharmaceuticals Ltd falling/rising?

2026-01-14 00:50:47

Recent Price Movement and Market Performance

The stock has been under pressure over the past week, registering a steep decline of 16.11%, significantly underperforming the Sensex’s modest 1.69% loss during the same period. Year-to-date, the stock has fallen by 16.43%, again far exceeding the benchmark’s 1.87% decline. This downward momentum has been persistent, with the stock experiencing six consecutive days of losses, cumulatively shedding over 16% in returns. On 13-Jan, the stock opened with a gap down of 4.47%, signalling immediate bearish sentiment among investors. Intraday, it touched a low of ₹126.55, marking a 4.85% drop from the previous close.

Technical Indicators and Investor Participation

From a technical standpoint, Bafna Pharmaceut...

Read full news article

Bafna Pharmaceuticals Ltd is Rated Sell

2026-01-04 10:10:27

Bafna Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 29 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Bafna Pharmaceuticals Ltd Hits Lower Circuit Amid Heavy Selling Pressure

2025-12-30 10:00:16

Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed intense selling pressure on 30 Dec 2025, hitting its lower circuit limit and closing at ₹151.89. The stock recorded a maximum daily loss of 2.24%, underperforming both its sector and the broader Sensex, as panic selling and unfilled supply weighed heavily on investor sentiment.

Read full news article

Bafna Pharmaceuticals Hits Lower Circuit Amid Heavy Selling Pressure

2025-12-29 10:00:32

Bafna Pharmaceuticals Ltd witnessed intense selling pressure on 29 Dec 2025, hitting its lower circuit limit and registering a maximum daily loss of 5%. The stock’s performance contrasted sharply with its sector and benchmark indices, reflecting a period of panic selling and unfilled supply that has unsettled investors.

Read full news article

Bafna Pharmaceuticals Hits Lower Circuit Amid Heavy Selling Pressure

2025-12-26 11:00:14

Bafna Pharmaceuticals Ltd witnessed a sharp decline on 26 Dec 2025, hitting its lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical company’s shares closed at ₹164.55, marking a maximum daily loss of 4.41%, amid heightened volatility and unfilled supply on the trading floor.

Read full news article

Bafna Pharmaceuticals Hits Upper Circuit Amid Strong Buying Pressure

2025-12-24 10:00:32

Bafna Pharmaceuticals Ltd witnessed robust buying interest on 24 Dec 2025, hitting its upper circuit limit with a 5.0% gain to close at ₹173.26. The stock outperformed its sector and broader market indices, reflecting heightened investor enthusiasm and a surge in demand that led to a regulatory trading freeze.

Read full news article

Bafna Pharmaceuticals Sees Shift in Market Assessment Amid Technical and Financial Developments

2025-12-24 08:20:52

Bafna Pharmaceuticals has experienced a notable revision in its market evaluation, reflecting changes across technical indicators, financial trends, valuation metrics, and overall quality considerations. This shift highlights evolving investor perspectives on the pharmaceutical company’s performance and outlook within the Pharmaceuticals & Biotechnology sector.

Read full news article

Bafna Pharmaceuticals Hits Upper Circuit Amid Strong Buying Pressure

2025-12-23 10:00:25

Bafna Pharmaceuticals Ltd witnessed robust buying interest on 23 Dec 2025, hitting its upper circuit limit with a maximum daily gain of 4.99%. The stock outperformed its sector and broader market indices, reflecting heightened investor enthusiasm and a surge in demand that led to a regulatory trading freeze.

Read full news article

View All News